Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10929539 | 1.00 | CA2 (0.34) | CA2PIK3CDALDH1A1EPHX2 | |
| SCHEMBL311120 | 1.00 | CA2 (0.34) | CA2PIK3CDALDH1A1EPHX2 | |
| SCHEMBL811322 | 1.00 | CA2 (0.34) | CA2PIK3CDALDH1A1EPHX2 | |
| SCHEMBL47033 | 0.91 | — | — | |
| SCHEMBL28164439 | 0.91 | PIK3CD (0.35) | PIK3CDALDH1A1 | |
| SCHEMBL5024988 | 0.89 | MEN1 (0.48) | ALDH1A1EPHX2 | |
| SCHEMBL987686 | 0.88 | EPHX2 (0.33) | ALDH1A1EPHX2 | |
| SCHEMBL863208 | 0.88 | EPHX2 (0.33) | ALDH1A1EPHX2 | |
| SCHEMBL863289 | 0.88 | EPHX2 (0.33) | ALDH1A1EPHX2 | |
| SCHEMBL987158 | 0.88 | EPHX2 (0.33) | ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| WO-2019183523-A1 | HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | CA2 1579/4885PIK3CD 4095/4885ALDH1A1 181/4885 |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | APLNR, MTNR1A, EDNRA | CA2 3534/4885PIK3CD 4383/4885ALDH1A1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.